Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | SNCA | P37840 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA3 | P07451 | 1/20 | 0.69 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.69 |
| ▸ | CA4 | P22748 | 1/20 | 0.69 |
| ▸ | CA6 | P23280 | 1/20 | 0.69 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.69 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30853135 | 1.00 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10HPGDALOX15 | |
| SCHEMBL731055 | 1.00 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10HPGDALOX15 | |
| SCHEMBL4188471 | 0.87 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10HPGDALOX15 | |
| SCHEMBL4188465 | 0.87 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10HPGDALOX15 | |
| SCHEMBL20456002 | 0.86 | EPHX2 (0.70) | KDM4EALDH1A1HSD17B10HPGDALOX15 | |
| SCHEMBL30290009 | 0.86 | EPHX2 (0.70) | KDM4EALDH1A1HSD17B10HPGDALOX15 | |
| SCHEMBL24968393 | 0.85 | GSK3B (0.64) | KDM4EALDH1A1HSD17B10HPGDALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL81317 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL81318 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL29636389 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191211-A1 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION | 2024-06-13 | — | — | US | disclosed |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-09 | — | — | US | disclosed |
| WO-2023215497-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215514-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| CN-108840871-B | 13-hydroxy cytisine cinnamate compound with anti-tumor activity and preparation method thereof | 西安泰科迈医药科技股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10233183-B1 | 13-hydroxysparteine cinnamic acid derivatives with anti-tumor activities and a method of preparing the same | SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-03-19 | — | — | US | disclosed |
| EP-2083844-A2 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2079479-A2 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008057208-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057208-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008051475-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051475-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1913016-A1 | MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007148135-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007016441-A1 | MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016441-A1 | MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233183-B1 | 13-hydroxysparteine cinnamic acid derivatives with anti-tumor activities and a method of preparing the same | CYP51A1, CYP46A1, HSD17B13 | KDM4E 4042/4885ALDH1A1 175/4885HSD17B10 62/4885 |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | BTD, HLCS, TYR | KDM4E 1476/4885ALDH1A1 268/4885HSD17B10 4239/4885 |
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | KDM4E 4055/4885ALDH1A1 1274/4885HSD17B10 1806/4885 |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, TGFB2 | KDM4E 4055/4885ALDH1A1 1274/4885HSD17B10 1806/4885 |
| US-11014873-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, SMAD2 | KDM4E 4041/4885ALDH1A1 1184/4885HSD17B10 1921/4885 |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, SMAD2 | KDM4E 3305/4885ALDH1A1 1967/4885HSD17B10 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.